{"id":490770,"date":"2025-08-22T11:16:10","date_gmt":"2025-08-22T17:16:10","guid":{"rendered":"https:\/\/billieparkernoticias.com\/?p=490770"},"modified":"2025-08-22T11:16:10","modified_gmt":"2025-08-22T17:16:10","slug":"anuncian-avances-en-tratamiento-de-alzheimer-sintomatico-temprano","status":"publish","type":"post","link":"https:\/\/fronteraveracruz.com\/?p=490770","title":{"rendered":"Anuncian avances en tratamiento de Alzheimer sintom\u00e1tico temprano."},"content":{"rendered":"<p>*La opini\u00f3n favorable del Comit\u00e9 de Medicamentos de Uso Humano (CHMP) ser\u00e1 remitida a la Comisi\u00f3n Europea para su decisi\u00f3n final, mientras nuevos datos del estudio TRAILBLAZER-ALZ 2 demuestran beneficios cl\u00ednicos sostenidos durante tres a\u00f1os.<\/p>\n<p><strong>Indian\u00e1polis, agosto 2025. \u2014<\/strong><strong>Eli Lilly and Company (NYSE: LLY)<\/strong> anunci\u00f3 un doble avance en el abordaje del Alzheimer sintom\u00e1tico temprano. Por un lado, las autoridades europeas emitieron una opini\u00f3n positiva sobre donanemab, terapia dirigida a adultos con caracter\u00edsticas gen\u00e9ticas espec\u00edficas y presencia confirmada de placas amiloides en el cerebro, una de las se\u00f1ales t\u00edpicas de la enfermedad. Por otro, los resultados de la extensi\u00f3n a largo plazo (LTE) del estudio de fase 3 TRAILBLAZER-ALZ 2 confirman que el medicamento mantiene beneficios cl\u00ednicos durante tres a\u00f1os, reforzando la importancia de la intervenci\u00f3n temprana.<\/p>\n<p>Aunque la aprobaci\u00f3n final en Europa est\u00e1 pendiente, este hito representa una esperanza significativa para los pacientes en etapas iniciales de Alzheimer<em>. \u201cEsta opini\u00f3n positiva representa un hito importante en nuestros esfuerzos por llevar esta terapia a los pacientes elegibles en toda Europa\u201d<\/em>, afirm\u00f3 Patrik Jonsson, vicepresidente ejecutivo y presidente de Lilly International. <em>\u201cEl tratamiento tiene el potencial de marcar una diferencia significativa, y en Lilly seguimos comprometidos con el avance de la ciencia a trav\u00e9s de ensayos cl\u00ednicos y programas en curso.\u201d<\/em> <sup>1<\/sup><\/p>\n<p><strong>Resultados clave del estudio TRAILBLAZER-ALZ 2 LTE<\/strong><\/p>\n<p>El estudio de extensi\u00f3n, presentado en la Conferencia Internacional de la Asociaci\u00f3n de Alzheimer (AAIC) 2025 en Toronto, mostr\u00f3 que:<\/p>\n<ul>\n<li>El inicio temprano con donanemab redujo el riesgo de progresi\u00f3n a la siguiente etapa de la enfermedad en un 27 % seg\u00fan la Escala Global de Calificaci\u00f3n de Demencia Cl\u00ednica (CDR-G), en comparaci\u00f3n con un inicio tard\u00edo.<sup>8<\/sup><\/li>\n<li>M\u00e1s del 75 % de los participantes alcanz\u00f3 la eliminaci\u00f3n de amiloide en las primeras 76 semanas de tratamiento.<sup>8<\/sup><\/li>\n<li>Despu\u00e9s de hasta 2.5 a\u00f1os desde la finalizaci\u00f3n del tratamiento, la re-acumulaci\u00f3n de placas amiloides se mantuvo lenta, a una tasa aproximada de 2.4 CL\/a\u00f1o. <sup>8<\/sup><\/li>\n<\/ul>\n<p>Estos hallazgos se suman a los resultados previos del TRAILBLAZER-ALZ 2 original, que demostraron que el medicamento puede ralentizar el deterioro cognitivo y funcional en fases tempranas.<\/p>\n<p>En Europa, hasta 6.9 millones de personas viven con Alzheimer, y se espera que esta cifra casi se duplique para 2050 debido al envejecimiento poblacional <sup>2<\/sup>. Aproximadamente un tercio de quienes presentan deterioro cognitivo leve o demencia leve por Alzheimer progresan a etapas m\u00e1s graves en un a\u00f1o.<\/p>\n<p><strong><em>Acerca de donanemab<\/em><\/strong><\/p>\n<p><em>Donanemab actualmente se comercializa en Estados Unidos y otros pa\u00edses como Jap\u00f3n, China, Reino Unido, Emiratos \u00c1rabes Unidos, Catar, Kuwait, Bar\u00e9in, Singapur*, Taiw\u00e1n, Brasil, M\u00e9xico y Australia. En pa\u00edses como Estados Unidos, Jap\u00f3n, China y muchos otros, Donanemab est\u00e1 aprobado para pacientes sin importar si tienen o no el gen ApoE4. Es la primera y \u00fanica terapia dirigida a las placas amiloides que cuenta con evidencia para respaldar la posibilidad de suspender el tratamiento una vez que las placas han sido eliminadas. Esto puede traducirse en menores costos y menos infusiones para los pacientes<sup>(5-8)<\/sup>.<\/em><\/p>\n<p><strong><em>Acerca de Lilly<\/em><\/strong><\/p>\n<p><em>Lilly es una compa\u00f1\u00eda de medicinas que transforma la ciencia en salud para mejorar la vida de las personas en el mundo. Durante casi 150 a\u00f1os, hemos liderado descubrimientos que cambian vidas, y hoy nuestros medicamentos ayudan a decenas de millones de personas en el planeta. Gracias al poder de la biotecnolog\u00eda, la qu\u00edmica y la medicina gen\u00e9tica, nuestros cient\u00edficos trabajan con sentido de urgencia para encontrar soluciones a algunos de los desaf\u00edos de salud m\u00e1s importantes del mundo: redefinir el cuidado de la diabetes, tratar la obesidad y reducir sus efectos m\u00e1s graves a largo plazo, avanzar en la lucha contra el Alzheimer, ofrecer tratamientos para enfermedades del sistema inmunol\u00f3gico y transformar los tipos de c\u00e1ncer m\u00e1s dif\u00edciles en enfermedades manejables. En cada paso hacia un mundo m\u00e1s saludable, nos gu\u00eda un solo prop\u00f3sito: mejorar la vida de millones de personas m\u00e1s. Esto incluye realizar ensayos cl\u00ednicos innovadores que reflejen la diversidad del mundo en el que vivimos y trabajar para que nuestros medicamentos sean accesibles y asequibles. Para m\u00e1s informaci\u00f3n, visita <\/em><a href=\"https:\/\/www.lilly.com\/latam\/\"><em>Lilly.com\/latam<\/em><\/a><em> o s\u00edguenos en <\/em><a href=\"https:\/\/www.facebook.com\/LillyLatam\"><em>Facebook<\/em><\/a><em>, <\/em><a href=\"https:\/\/www.instagram.com\/lilly_latam\/\"><em>Instagram<\/em><\/a><em>, <\/em><a href=\"https:\/\/www.linkedin.com\/showcase\/lilly-latam\/posts\/?feedView=all\"><em>LinkedIn<\/em><\/a><em> y <\/em><a href=\"https:\/\/www.tiktok.com\/@lillylatamoficial\"><em>TikTok<\/em><\/a><em>. <\/em><em>P-LLY<\/em><\/p>\n<p>&nbsp;<\/p>\n<p><strong>Referencias<\/strong><\/p>\n<ol>\n<li>Gustavsson, A., et al. Global estimates on the number of persons across the Alzheimer\u2019s disease continuum. Alzheimer\u2019s &amp; Dementia. 2023;19:658-670. https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/full\/10.1002\/alz.12694.<\/li>\n<li>Alzheimer Europe. Prevalence of dementia in Europe. https:\/\/www.alzheimer-europe.org\/dementia\/prevalence-dementia-europe.<\/li>\n<li>Potashman M, et al. Estimating progression rates across the spectrum of Alzheimer\u2019s disease for amyloid-positive individuals. Neurol Ther. 2021;10(2):941-953. doi:10.1007\/s40120-021-00272-1.<\/li>\n<li>Sims JR, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023;330(6):512-527. doi:10.1001\/jama.2023.13239.<\/li>\n<li>Boustani M, et al. Assessing the Cost-effectiveness&#8230; Clin Ther. 2022;44(11):1449-1462. doi:10.1016\/j.clinthera.2022.09.008.<\/li>\n<li>Ross EL, et al. Cost-effectiveness of Aducanumab and Donanemab&#8230; JAMA Neurol. 2022;79(5):478-487. doi:10.1001\/jamaneurol.2022.0315.<\/li>\n<li>Mattke S, et al. Implications of Treatment Duration&#8230; Clinical Trials on Alzheimer\u2019s Disease. Oct. 24-27, 2023.<\/li>\n<li>Eli Lilly. A Study of Donanemab (LY3002813)&#8230; ClinicalTrials.gov identifier: NCT04437511. Updated May 4, 2025. https:\/\/clinicaltrials.gov\/study\/NCT04437511.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>*La opini\u00f3n favorable del Comit\u00e9 de Medicamentos de Uso Humano (CHMP) ser\u00e1 remitida a la Comisi\u00f3n Europea para su decisi\u00f3n final, mientras nuevos datos del estudio TRAILBLAZER-ALZ 2 demuestran beneficios cl\u00ednicos sostenidos durante tres a\u00f1os. Indian\u00e1polis, agosto 2025. \u2014Eli Lilly and Company (NYSE: LLY) anunci\u00f3 un doble avance en el abordaje del Alzheimer sintom\u00e1tico temprano&#8230;.<\/p>\n","protected":false},"author":3,"featured_media":444909,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_kad_post_transparent":"","_kad_post_title":"","_kad_post_layout":"","_kad_post_sidebar_id":"","_kad_post_content_style":"","_kad_post_vertical_padding":"","_kad_post_feature":"","_kad_post_feature_position":"","_kad_post_header":false,"_kad_post_footer":false,"_kad_post_classname":"","footnotes":""},"categories":[18,229],"tags":[2174],"class_list":["post-490770","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-noticias-de-ultima-hora","category-salud","tag-alzheimer"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Anuncian avances en tratamiento de Alzheimer sintom\u00e1tico temprano. - Frontera Veracruz<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fronteraveracruz.com\/?p=490770\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Anuncian avances en tratamiento de Alzheimer sintom\u00e1tico temprano. - Frontera Veracruz\" \/>\n<meta property=\"og:description\" content=\"*La opini\u00f3n favorable del Comit\u00e9 de Medicamentos de Uso Humano (CHMP) ser\u00e1 remitida a la Comisi\u00f3n Europea para su decisi\u00f3n final, mientras nuevos datos del estudio TRAILBLAZER-ALZ 2 demuestran beneficios cl\u00ednicos sostenidos durante tres a\u00f1os. Indian\u00e1polis, agosto 2025. \u2014Eli Lilly and Company (NYSE: LLY) anunci\u00f3 un doble avance en el abordaje del Alzheimer sintom\u00e1tico temprano....\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fronteraveracruz.com\/?p=490770\" \/>\n<meta property=\"og:site_name\" content=\"Frontera Veracruz\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/share\/1CtNrbq7Bz\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-22T17:16:10+00:00\" \/>\n<meta name=\"author\" content=\"Billie Parker Noticias\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Billie Parker Noticias\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/fronteraveracruz.com\\\/?p=490770#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fronteraveracruz.com\\\/?p=490770\"},\"author\":{\"name\":\"Billie Parker Noticias\",\"@id\":\"https:\\\/\\\/fronteraveracruz.com\\\/#\\\/schema\\\/person\\\/3b5b8f1e99acdc9e32ee42c7eef2af93\"},\"headline\":\"Anuncian avances en tratamiento de Alzheimer sintom\u00e1tico temprano.\",\"datePublished\":\"2025-08-22T17:16:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/fronteraveracruz.com\\\/?p=490770\"},\"wordCount\":887,\"publisher\":{\"@id\":\"https:\\\/\\\/fronteraveracruz.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/fronteraveracruz.com\\\/?p=490770#primaryimage\"},\"thumbnailUrl\":\"\",\"keywords\":[\"Alzheimer\"],\"articleSection\":[\"Noticias de \u00faltima hora\",\"Salud\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/fronteraveracruz.com\\\/?p=490770\",\"url\":\"https:\\\/\\\/fronteraveracruz.com\\\/?p=490770\",\"name\":\"Anuncian avances en tratamiento de Alzheimer sintom\u00e1tico temprano. - Frontera Veracruz\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fronteraveracruz.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/fronteraveracruz.com\\\/?p=490770#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/fronteraveracruz.com\\\/?p=490770#primaryimage\"},\"thumbnailUrl\":\"\",\"datePublished\":\"2025-08-22T17:16:10+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/fronteraveracruz.com\\\/?p=490770#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/fronteraveracruz.com\\\/?p=490770\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/fronteraveracruz.com\\\/?p=490770#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/fronteraveracruz.com\\\/?p=490770#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inicio\",\"item\":\"https:\\\/\\\/fronteraveracruz.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Anuncian avances en tratamiento de Alzheimer sintom\u00e1tico temprano.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/fronteraveracruz.com\\\/#website\",\"url\":\"https:\\\/\\\/fronteraveracruz.com\\\/\",\"name\":\"Frontera Veracruz\",\"description\":\"Noticias C\u00f3rdoba \u00b7 Orizaba \u00b7 Veracruz\",\"publisher\":{\"@id\":\"https:\\\/\\\/fronteraveracruz.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/fronteraveracruz.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/fronteraveracruz.com\\\/#organization\",\"name\":\"Frontera Veracruz\",\"url\":\"https:\\\/\\\/fronteraveracruz.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/fronteraveracruz.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/fronteraveracruz.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/logo-header.png\",\"contentUrl\":\"https:\\\/\\\/fronteraveracruz.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/logo-header.png\",\"width\":600,\"height\":220,\"caption\":\"Frontera Veracruz\"},\"image\":{\"@id\":\"https:\\\/\\\/fronteraveracruz.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/share\\\/1CtNrbq7Bz\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/fronteraveracruz.com\\\/#\\\/schema\\\/person\\\/3b5b8f1e99acdc9e32ee42c7eef2af93\",\"name\":\"Billie Parker Noticias\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5f4260f6f8d7662d1d639b4ad29baab2b3768c8300be062ab97691f061e9207a?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5f4260f6f8d7662d1d639b4ad29baab2b3768c8300be062ab97691f061e9207a?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5f4260f6f8d7662d1d639b4ad29baab2b3768c8300be062ab97691f061e9207a?s=96&d=mm&r=g\",\"caption\":\"Billie Parker Noticias\"},\"url\":\"https:\\\/\\\/fronteraveracruz.com\\\/?author=3\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Anuncian avances en tratamiento de Alzheimer sintom\u00e1tico temprano. - Frontera Veracruz","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fronteraveracruz.com\/?p=490770","og_locale":"es_MX","og_type":"article","og_title":"Anuncian avances en tratamiento de Alzheimer sintom\u00e1tico temprano. - Frontera Veracruz","og_description":"*La opini\u00f3n favorable del Comit\u00e9 de Medicamentos de Uso Humano (CHMP) ser\u00e1 remitida a la Comisi\u00f3n Europea para su decisi\u00f3n final, mientras nuevos datos del estudio TRAILBLAZER-ALZ 2 demuestran beneficios cl\u00ednicos sostenidos durante tres a\u00f1os. Indian\u00e1polis, agosto 2025. \u2014Eli Lilly and Company (NYSE: LLY) anunci\u00f3 un doble avance en el abordaje del Alzheimer sintom\u00e1tico temprano....","og_url":"https:\/\/fronteraveracruz.com\/?p=490770","og_site_name":"Frontera Veracruz","article_publisher":"https:\/\/www.facebook.com\/share\/1CtNrbq7Bz\/","article_published_time":"2025-08-22T17:16:10+00:00","author":"Billie Parker Noticias","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Billie Parker Noticias","Tiempo de lectura":"4 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/fronteraveracruz.com\/?p=490770#article","isPartOf":{"@id":"https:\/\/fronteraveracruz.com\/?p=490770"},"author":{"name":"Billie Parker Noticias","@id":"https:\/\/fronteraveracruz.com\/#\/schema\/person\/3b5b8f1e99acdc9e32ee42c7eef2af93"},"headline":"Anuncian avances en tratamiento de Alzheimer sintom\u00e1tico temprano.","datePublished":"2025-08-22T17:16:10+00:00","mainEntityOfPage":{"@id":"https:\/\/fronteraveracruz.com\/?p=490770"},"wordCount":887,"publisher":{"@id":"https:\/\/fronteraveracruz.com\/#organization"},"image":{"@id":"https:\/\/fronteraveracruz.com\/?p=490770#primaryimage"},"thumbnailUrl":"","keywords":["Alzheimer"],"articleSection":["Noticias de \u00faltima hora","Salud"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/fronteraveracruz.com\/?p=490770","url":"https:\/\/fronteraveracruz.com\/?p=490770","name":"Anuncian avances en tratamiento de Alzheimer sintom\u00e1tico temprano. - Frontera Veracruz","isPartOf":{"@id":"https:\/\/fronteraveracruz.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/fronteraveracruz.com\/?p=490770#primaryimage"},"image":{"@id":"https:\/\/fronteraveracruz.com\/?p=490770#primaryimage"},"thumbnailUrl":"","datePublished":"2025-08-22T17:16:10+00:00","breadcrumb":{"@id":"https:\/\/fronteraveracruz.com\/?p=490770#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fronteraveracruz.com\/?p=490770"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/fronteraveracruz.com\/?p=490770#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/fronteraveracruz.com\/?p=490770#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inicio","item":"https:\/\/fronteraveracruz.com\/"},{"@type":"ListItem","position":2,"name":"Anuncian avances en tratamiento de Alzheimer sintom\u00e1tico temprano."}]},{"@type":"WebSite","@id":"https:\/\/fronteraveracruz.com\/#website","url":"https:\/\/fronteraveracruz.com\/","name":"Frontera Veracruz","description":"Noticias C\u00f3rdoba \u00b7 Orizaba \u00b7 Veracruz","publisher":{"@id":"https:\/\/fronteraveracruz.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fronteraveracruz.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/fronteraveracruz.com\/#organization","name":"Frontera Veracruz","url":"https:\/\/fronteraveracruz.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/fronteraveracruz.com\/#\/schema\/logo\/image\/","url":"https:\/\/fronteraveracruz.com\/wp-content\/uploads\/2026\/06\/logo-header.png","contentUrl":"https:\/\/fronteraveracruz.com\/wp-content\/uploads\/2026\/06\/logo-header.png","width":600,"height":220,"caption":"Frontera Veracruz"},"image":{"@id":"https:\/\/fronteraveracruz.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/share\/1CtNrbq7Bz\/"]},{"@type":"Person","@id":"https:\/\/fronteraveracruz.com\/#\/schema\/person\/3b5b8f1e99acdc9e32ee42c7eef2af93","name":"Billie Parker Noticias","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/5f4260f6f8d7662d1d639b4ad29baab2b3768c8300be062ab97691f061e9207a?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/5f4260f6f8d7662d1d639b4ad29baab2b3768c8300be062ab97691f061e9207a?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5f4260f6f8d7662d1d639b4ad29baab2b3768c8300be062ab97691f061e9207a?s=96&d=mm&r=g","caption":"Billie Parker Noticias"},"url":"https:\/\/fronteraveracruz.com\/?author=3"}]}},"_links":{"self":[{"href":"https:\/\/fronteraveracruz.com\/index.php?rest_route=\/wp\/v2\/posts\/490770","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fronteraveracruz.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fronteraveracruz.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fronteraveracruz.com\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/fronteraveracruz.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=490770"}],"version-history":[{"count":0,"href":"https:\/\/fronteraveracruz.com\/index.php?rest_route=\/wp\/v2\/posts\/490770\/revisions"}],"wp:attachment":[{"href":"https:\/\/fronteraveracruz.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=490770"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fronteraveracruz.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=490770"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fronteraveracruz.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=490770"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}